Stryker SYK Orthopaedics — Reclassification to: cost of sales

Other segment segments

Similar metrics at other companies

CHDConsolidating Reclassification — Cost Of Revenue

$17.9M+9.1%

LZBRetail — Cost of Sales

$116.98M+7.6%

LZBWholesale — Cost of Sales

$284.82M-4.3%

BBLicensing — Cost of Sales

$1.5M-6.3%

BBQNX — Cost of Sales

$10.4M-7.1%

GMEAustralia — Cost of Sales

$65.3M+18.7%

FAQ

What is Stryker's orthopaedics — reclassification to: cost of sales?

Stryker (SYK) reported orthopaedics — reclassification to: cost of sales of $823M in Q1 2026.

How has Stryker's orthopaedics — reclassification to: cost of sales changed year-over-year?

Stryker's orthopaedics — reclassification to: cost of sales increased by 6.2% year-over-year, from $775M to $823M.

What is the long-term trend for Stryker's orthopaedics — reclassification to: cost of sales?

Over 3 years (2022 to 2025), Stryker's orthopaedics — reclassification to: cost of sales has grown at a 12.3% compound annual growth rate (CAGR), from $1.92B to $2.72B.

What does orthopaedics — reclassification to: cost of sales mean?

This represents specific costs previously categorized elsewhere that have been reclassified into the cost of goods sold for the Orthopaedics business segment. It reflects adjustments in accounting treatment to better align direct production or service delivery expenses with revenue generation. Monitoring this helps investors understand shifts in gross margin reporting and the underlying cost structure of orthopedic product manufacturing.